drugset / Trial / NCT00346879

Study to Determine Effective Dosing of Fondaparinux in Obese Persons

NCT00346879

RandomizedSingle-groupOpen-labelTreatment

Summary

This is a prospective open-label study comparing two dosing regimens of fondaparinux, which is used to prevent deep vein thrombosis, in morbidly obese volunteers.

Timeline

Start
2006-08
Primary completion
2008-12
Completion
2009-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Fondaparinux Other / unclassified 0.03 mg/kg
Subject Fondaparinux Other / unclassified 2.5 mg

Indications